Samsung Biologics expands into peptides with $1.8b PolyPeptide deal

Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its multi-modality and global manufacturing capabilities.

The transaction is expected to be completed by the end of this year to mark the biggest takeover in the history of Korea’s biopharmaceutical industry, according to the company, which is Korea’s leading contract development and manufacturing organization, or CDMO.

As PolyPeptide's shares ar ...